BusinessAchillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement WorkshopBy Nasdaq OMXSep 6, 2016, 10:05 AM UTC
BusinessAchillion to Present at Two Upcoming Investor ConferencesBy Nasdaq OMXSep 1, 2016, 10:05 AM UTC
BusinessHemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine RepublicBy Nasdaq OMXAug 26, 2016, 12:30 AM UTC
BusinessAchillion to Present at the 2016 Wedbush PacGrow Healthcare ConferenceBy Nasdaq OMXAug 9, 2016, 10:05 AM UTC
BusinessHemispherx Biopharma Retains Huron Consulting Group to Support Partnering Strategy and Planning for Alferon® and Ampligen®By Nasdaq OMXApr 20, 2016, 12:30 PM UTC
BusinessFEI Partners with Five Pharmaceutical Companies, the Medical Research Council and the University of Cambridge to form Cryo-EM Research ConsortiumBy Nasdaq OMXApr 4, 2016, 10:05 AM UTC
BusinessHemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2015By Nasdaq OMXMar 29, 2016, 9:41 PM UTC
BusinessHemispherx Biopharma Announces Conference Call to Discuss Management Changes and Provide Corporate Update on March 30, 2016By Nasdaq OMXMar 22, 2016, 12:30 PM UTC
